1. The cases of Guatemala, El Salvador, Honduras, Nicaragua, Dominican Republic and Costa Rica (in process)

2.  Unnecessary limitations for applying the safeguards established in the TRIPS Agreement and affirmed in the Doha Declaration, especially for issuing compulsory licences – the only remaining means to restore competition  Lack of any solutions to by-pass the CAFTA provision that obliges to reject the market approval of generics relying on previously submitted test data when that product is on patent – e.g. an option could be to determine that a compulsory licence involves the suspension of this exclusivity

3.  Using all possibilities for positive interpretation of international/regional trade agreements in order to give priority to the right to health over profit  Urging to establish a competent decision body for determining the appropriate measures in order to protect access to medicines against exclusive rights  Building international alliances which are capable to promote evaluations and modifications of the harmful provisions of TRIPS Agreement & DR-CAFTA  Should we formulate a complementary MDG: “to halt and begin to reverse the spread of monopoly rights on vital knowledge”

4. Source: WHO price reporting mechanism, own calculations